000			02084nam a2200361 4500
001			ESSALUD
005			20260820161112.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aBhoj, Vijay G. _eAutor _954193
245			_aKidney transplantation in two highly sensitized candidates after CAR T-Cell therapy
300			_apáginas: 2117-2125
520			_aHLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy.
650			_aENFERMEDAD RENAL CRÓNICA _932213
650			_aTRASPLANTE DE RIÑÓN _913898
650			_aCIRUGÍA GENERAL _944496
650			_aCÉLULAS T _954097
650			_aTRASPLANTE _97847
700			_aKaminski, María _954194
700			_aZhao, Huiwu _954195
700			_aJackson, Kyle _954196
700			_aWang, Wei _954197
700			_aLiu, Chengyang _954198
700			_aMontgomery, Robert A. _954199
700			_aAli, Nicole _954200
700			_aMangiola, Massimo _954201
700			_aSpitzer, Thomas R. _954202
700			_aSafa, Kassem _954203
773	0		_022717 _922648 _dMassachusetts NEJM Group _oNEJM011 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-20 _zsqb
999			_c22842 _d22842